<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047185</url>
  </required_header>
  <id_info>
    <org_study_id>PHA022121-C301</org_study_id>
    <secondary_id>2021-000227-13</secondary_id>
    <nct_id>NCT05047185</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II</brief_title>
  <acronym>HAE CHAPTER-1</acronym>
  <official_title>A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharvaris Netherlands B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharvaris Netherlands B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of PHA-022121 administered orally for&#xD;
      prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). The&#xD;
      study will have 3 parallel arms and approximately 30 patients will be equally randomized to&#xD;
      one of two dose regimens of PHA-022121 or matching placebo. The screening period is up to 8&#xD;
      weeks and the treatment period is 12 weeks in duration. The study will assess the efficacy of&#xD;
      PHA-022121 as prophylaxis against HAE attacks, and safety of each dose of PHA-022121 compared&#xD;
      with placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of investigator-confirmed HAE attacks</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of investigator-confirmed moderate or severe HAE attacks during the treatment period</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of investigator-confirmed HAE attacks requiring acute treatment during the treatment period</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving reduction in attack rate during the treatment period relative to baseline</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that are attack-free during the treatment period</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of days with angioedema symptoms during the treatment period</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first investigator-confirmed HAE attack in the treatment period</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of investigator-confirmed HAE attacks resulting in a visit to the emergency department or an admission to hospital</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hereditary Angioedema</condition>
  <condition>Hereditary Angioedema Type I</condition>
  <condition>Hereditary Angioedema Type II</condition>
  <condition>Hereditary Angioedema Types I and II</condition>
  <condition>Hereditary Angioedema Attack</condition>
  <condition>Hereditary Angioedema With C1 Esterase Inhibitor Deficiency</condition>
  <condition>Hereditary Angioedema - Type 1</condition>
  <condition>Hereditary Angioedema - Type 2</condition>
  <condition>C1 Esterase Inhibitor Deficiency</condition>
  <condition>C1 Inhibitor Deficiency</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BID low dose of PHA-022121</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BID high dose of PHA-022121</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BID placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHA-022121</intervention_name>
    <description>PHA-022121 softgel capsules for oral use (PHVS416)</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHA-022121</intervention_name>
    <description>PHA-022121 PHA-022121 softgel capsules for oral use (PHVS416)</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules for oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent form&#xD;
&#xD;
          -  Diagnosis of HAE type I or II&#xD;
&#xD;
          -  Documented history of at least 3 HAE attacks within the last 3 consecutive months&#xD;
             prior to screening, or a minimum of 2 HAE attacks during the screening period&#xD;
&#xD;
          -  Reliable access and experience to use standard of care acute attack medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Clinically significant abnormal electrocardiogram&#xD;
&#xD;
          -  Any other systemic disease or significant disease or disorder that would interfere&#xD;
             with the patient's safety or ability to participate in the study&#xD;
&#xD;
          -  Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens,&#xD;
             anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to&#xD;
             enrolment&#xD;
&#xD;
          -  Abnormal hepatic function&#xD;
&#xD;
          -  Abnormal renal function&#xD;
&#xD;
          -  History of alcohol or drug abuse within defined period, or current evidence of&#xD;
             substance dependence or abuse&#xD;
&#xD;
          -  Participation in any other investigational drug study within defined period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Riedl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego, La Jolla, California, United States</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emel Aygören-Pürsün, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Frankfurt - Goethe University, Frankfurt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pharvaris Clinical Team</last_name>
    <phone>+31 (71) 203-6410</phone>
    <email>clinicaltrials@pharvaris.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAE</keyword>
  <keyword>HAE Type I</keyword>
  <keyword>HAE Type II</keyword>
  <keyword>Oral Treatment</keyword>
  <keyword>Bradykinin B2 Receptor Antagonist</keyword>
  <keyword>PHVS416</keyword>
  <keyword>PHA121</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Hereditary Angioedema Types I and II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

